Carregando...

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study

Ruxolitinib is the only approved therapy for myelofibrosis (MF). However, its use in patients with myeloproliferative neoplasms (MPN) not participating in clinical studies has been poorly described. We reviewed the medical records of 45 patients (35 MF, 10 others) treated with ruxolitinib at our cen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Principais autores: Naqvi, Kiran, Daver, Naval, Pemmaraju, Naveen, Bose, Prithviraj, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5521009/
https://ncbi.nlm.nih.gov/pubmed/27494751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2016.1217528
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!